Abstract
Background: Trastuzumab emtansine (T-DM1) has been widely used for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) patients who previously received trastuzumab (Tmab) and a taxane since 2013 in Japan. However, there is a lack of evidence for treatment outcomes after exposure to T-DM1 in Japanese HER2-positive MBC patients. This study aimed to describe the survival outcomes of patients with HER2-positive MBC who received subsequent treatment after T-DM1 and clarify the predictive factors of their prognosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
